Tissue & cytoskeletal research
TB-500 5 mg
A synthetic fragment related to thymosin beta-4. Studied in preclinical models for its role in cell migration and tissue remodelling processes.
What it is
TB-500 is a synthetic peptide related to a region of the naturally occurring protein thymosin beta-4. It is supplied as a research chemical, not as a registered medicine.
Mechanism being studied
Laboratory research has examined actin-binding activity and effects on cell migration, which are relevant to wound-repair biology. Translation of these observations to clinical outcomes has not been established.
Human evidence
Human clinical evidence is minimal. Related thymosin beta-4 formulations have been investigated in early-phase studies, but TB-500 itself lacks adequate controlled trials in people.
Safety considerations
Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.
Regulatory status
Not an approved medicine. Prohibited in sport by WADA. Supply and possession rules vary by jurisdiction — confirm locally.
Key references
- Peer-reviewed thymosin beta-4 literature indexed in PubMed.
- World Anti-Doping Agency Prohibited List.
- SAHPRA — guidance on unregistered health products.
References are provided as reading directions for professionals. They do not constitute endorsement of any use.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.